Biocon Biologics partners with National Cancer Society of Malaysia
Biocon Biologics has partnered with the National Cancer Society of Malaysia (NCSM), a prominent not-for-profit cancer organization, to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia.
Biocon Biologics will provide quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility and affordability in Malaysia.
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints.
The MoU was signed during the National Cancer Congress Malaysia 2025 event, emphasizing a commitment to improving patient-centric healthcare.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
5 days ago
- Economic Times
Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million
Synopsis Intas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. This acquisition strengthens Intas's position as a global leader in pegfilgrastim. Accord BioPharma, Intas's U.S. specialty business, will continue commercializing UDENYCA to reduce infection risk in cancer patients undergoing myelosuppressive chemotherapy. Agencies Intas Pharma has completed the acquisition of UDENYCA for $558 million, the company said in a release. UDENYCA is a biosimilar to Neulasta or Pegfilgrastim. It is used to treat side effects of radiation therapy in cancer patients such as recurrent infections. Intas acquired the biosimilar drug from California-based Coherus Life Sciences in December 2024.'This acquisition cements our position as a global leader in pegfilgrastim and allows us to further expand our specialty division across key international markets,' said Binesh Chudgar, Intas Pharma's chairman and managing Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, have acquired UDENYCA. With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia, the company's release stated.'The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavour to innovate and expand in the biosimilar space,' said Chrys Kokino, President, USA, Accord BioPharma.
Time of India
08-08-2025
- Time of India
Biocon sees GLP-1 weight-loss therapy as a future growth driver
Biocon will continue to deepen its push in the insulin business, even as the biopharmaceutical company will have GLP-1 weight-loss therapy as one of the key focus areas in its future growth strategy, Shreehas Tambe, chief executive of Biocon Biologics, told ET on Friday. Leveraging decades of experience in insulin, the Bengaluru-based company aims to gain an edge over rivals in the race for copycats of GLP-1 drugs, which are gaining popularity as an effective treatment for glucose control as well as weight management. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Biocon has completed bioequivalence studies in India for semaglutide , a GLP-1 drug, and is progressing to Phase-III trials, which it expects to conclude by the end of calendar year 2026. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 'Subsequent regulatory approval is anticipated in CY 2027, after which we will launch the product in India through a partner,' said Tambe, who is also the managing director of the biosimilar and biologics subsidiary of Biocon. Novo Nordisk's blockbuster weight-loss drug semaglutide (branded Wegovy) will go off patent in India in March. Live Events On being asked about the disruption in the diabetes drug segment due to the inroads by GLP-1 products, Tambe said: 'The disruption (due to GLP-1) is complementary to insulin. We are bullish on both insulin and GLP-1.' 'The originators who brought GLP1s are the insulin companies, and they were able to do that because it is synergistic. Synergy not just in terms of the therapy area but also in terms of operations, touchpoints for prescribers, healthcare givers and customers,' said Tambe, who is also the company's managing director. Biocon has both biosimilar insulins and GLP-1 peptides that mimic a naturally occurring gut hormone that controls sugar levels and appetite. 'That is what differentiates us from the rest,' he said. 'Having been close to the market will give an advantage because it requires a lot of expertise as the drug is in the form of an injectable, given in a device, is a chronic treatment and hence requires a long-term relationship with patients who need to be trained on those devices,' said Tambe. 'All of these we have been able to do with our insulins in the past several years in 80-plus countries that is why we feel confident and we are developing both portfolios that are complementary to each other.' The company got US Food and Drug Administration approval for insulin aspart, its second interchangeable biosimilar insulin, deepening its presence in the US insulin market. 'The US FDA approval of Kirsty (biosimilar aspart) builds on the strong foundation established with Semglee (biosimilar insulin glargine), enabling us to offer patients the full range of affordable short- and long-acting insulin therapies,' he said. 'Insulin aspart we will enter by the end of this fiscal,' he said. The company got approval for diabetes drug liraglutide in India in June. The drug, used in treating type-2 diabetes, has already launched in the UK and the EU. 'We are working towards expeditiously launching the drug product through our commercialisation partners in India,' said Tambe. 'The biggest concern for the year ahead is external risks to the business, such as potential tariff and geopolitical headwinds. Some of these things are not in our control but that is the biggest concern for the whole industry too,' he said.
Time of India
04-08-2025
- Time of India
What types of cancers are most responsive to immunotherapy in patients
Immunotherapy is proving to be one of the most revolutionary steps in contemporary cancer treatment. In contrast to the conventional methods like chemotherapy and radiation, immunotherapy utilizes the immunity of the human body to mark and eliminate cancer cells. It brings hope, particularly for those patients who have failed to respond to the conventional approach. How immunotherapy works Immunotherapy strengthens the immune system to better see and destroy cancer. This is done either by augmenting the body's own defenses or by arming it with man-made proteins and antibodies that enable it to better attack cancer cells. Not a cure for every type of cancer, immunotherapy has been truly successful in a broad spectrum of cancers and continues to evolve. Important forms of immunotherapy 1. Immune Checkpoint Inhibitors Checkpoint inhibitors act by inhibiting the proteins that shield cancer from immune cells. The most common checkpoint inhibitors are: PD-1 Inhibitors: Pembrolizumab Nivolumab PD-L1 Inhibitors: Atezolizumab Avelumab Durvalumab 2. Monoclonal Antibodies (MAbs) These laboratory-made molecules function as replacement antibodies that can replace, stimulate, or copy the immune system's attack against cancer cells. Brentuximab Trastuzumab Bevacizumab Cetuximab 3. CAR T-Cell Therapy It is an individualized treatment that alters the T cells of a patient to identify and destroy cancer cells more effectively. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like The Best Method for a Flat Stomach After 50 (It's Genius!) Lulutox Undo It has been exceptionally effective in cancers affecting the blood, such as lymphoma and leukemia. Immunomodulators They are drugs that manage the immune response in certain types of cancer. Some of them are: BCG (for cancer of the bladder) Imiquimod cream (for skin cancer) 5. Cancer Vaccines Vaccines against viruses such as HPV have demonstrated a clear advantage in the prevention of cervical and other cancers due to HPV. Cancers responding well to immunotherapy Immunotherapy has made notable strides in treating various cancers, either alone or in combination with other treatments: 1) Brain Cancer - Medications such as Dostarlimab, Pembrolizumab, and Bevacizumab have enhanced treatment outcomes. 2) Breast and Cervical Cancer - The same medications have also demonstrated additional success in increasing survival rates. 3)Colorectal Cancer - Treatments consist of Bevacizumab, Cetuximab, Panitumumab, and Ramucirumab. 4) Lung Cancer – Amivantamab and other checkpoint inhibitors and monoclonal antibodies, have become routine in most cases. 5)Lymphoma - Treatments such as Retuximab, Brentuximab, and CAR T-cell therapy are making a huge difference. 6) Melanoma - One of the most malignant skin cancers, melanoma is highly sensitive to immunotherapy, so it's often the treatment of choice. 7)Other common cancers - Head and neck, cervical, intestinal, oesophageal, pancreato-biliary, kidney, and genito-urinary cancers also yield good results with immunotherapy. As continuing research hones and individualizes these treatments, immunotherapy is a potent weapon in the oncologist's arsenal. Its capacity to treat where other means fail already has altered the lives of countless patients and it holds still greater promise for the future. Immunotherapy is not only a therapy - it's a revolution in the war against cancer.
